1. Home
  2. OCFC vs RCUS Comparison

OCFC vs RCUS Comparison

Compare OCFC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OceanFirst Financial Corp.

OCFC

OceanFirst Financial Corp.

HOLD

Current Price

$20.12

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$21.61

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCFC
RCUS
Founded
1902
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
3.1B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
OCFC
RCUS
Price
$20.12
$21.61
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$21.50
$29.38
AVG Volume (30 Days)
320.8K
2.0M
Earning Date
01-22-2026
10-28-2025
Dividend Yield
3.99%
N/A
EPS Growth
N/A
N/A
EPS
1.30
N/A
Revenue
$378,558,000.00
$240,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.51
N/A
P/E Ratio
$15.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.29
$6.50
52 Week High
$20.60
$26.40

Technical Indicators

Market Signals
Indicator
OCFC
RCUS
Relative Strength Index (RSI) 67.76 43.57
Support Level $19.06 $24.75
Resistance Level $20.60 $26.10
Average True Range (ATR) 0.55 1.50
MACD 0.16 -0.41
Stochastic Oscillator 84.13 21.97

Price Performance

Historical Comparison
OCFC
RCUS

About OCFC OceanFirst Financial Corp.

OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: